Cargando…

COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic

Detalles Bibliográficos
Autores principales:	Ryan, Emory, Lopez, Grisel, Balwani, Manisha, Barbouth, Deborah, Burrow, T. Andrew, Ginns, Edward, Goker-Alpan, Ozlem, Grabowski, Gregory, Kartha, Reena, Kishnani, Priya, Lau, Heather, Lee, Chung, Mistry, Pramod, Maegawa, Gustavo, Packman, Seymour, Prada, Carlos, Rosenbloom, Barry, Lal, Tamanna Roshan, Schiffmann, Raphael, Weinreb, Neal, Sidransky, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849417/ http://dx.doi.org/10.1016/j.ymgme.2020.12.223

Ejemplares similares

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown
por: Ginns, Edward I., et al.
Publicado: (2021)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

The Spectrum of Neurological Manifestations Associated with Gaucher Disease
por: Roshan Lal, Tamanna, et al.
Publicado: (2017)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Longitudinal evaluation of olfactory function in individuals with Gaucher disease and GBA1 mutation carriers with and without Parkinson's disease
por: Lopez, Grisel J., et al.
Publicado: (2022)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes
por: Orenstein, Marissa, et al.
Publicado: (2014)

Modeling potential interactions between oral Gaucher disease treatment and investigational COVID-19 therapies
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2021)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Efferocytosis is impaired in Gaucher macrophages
por: Aflaki, Elma, et al.
Publicado: (2017)

Bilateral femoral osteolytic lesions in a patient with type 3 Gaucher disease
por: Teefe, Enock, et al.
Publicado: (2015)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases
por: Ivanova, Margarita M., et al.
Publicado: (2019)

Rapid-Onset Dystonia and Parkinsonism in a Patient With Gaucher Disease
por: Hertz, Ellen, et al.
Publicado: (2023)

The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease
por: Stiles, Ashlee R., et al.
Publicado: (2021)

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
por: Sims, KB, et al.
Publicado: (2008)

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
por: Ivanova, Margarita, et al.
Publicado: (2021)

Patients with Gaucher disease display systemic oxidative stress dependent on therapy status
por: Kartha, Reena V., et al.
Publicado: (2020)

Biofabrication of an in-vitro bone model for Gaucher disease
por: Banerjee, Dishary, et al.
Publicado: (2023)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease
por: Limgala, Renuka Pudi, et al.
Publicado: (2016)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2022)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages
por: Aflaki, Elma, et al.
Publicado: (2015)

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_36ir15217a1al3ql3f1t3d5brs